<DOC>
	<DOCNO>NCT01993212</DOCNO>
	<brief_summary>This Randomized , Double Blind , Placebo-Controlled , Multi-Center Phase III Study Men Acquired Hypogonadotropic Hypogonadism Compare Changes Testosterone Sperm Concentration Following Treatment 12.5 mg 25 mg Androxal AndroGel 1.62 % .</brief_summary>
	<brief_title>A Randomized , Double Blind , Placebo-Controlled , Multi-Center Phase III Study Men With Acquired Hypogonadotropic Hypogonadism Compare Changes Testosterone Sperm Concentration Following Treatment With 12.5 mg 25 mg Androxal AndroGel 1.62 %</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>Overweight ( BMI 25 42 kg/m2 inclusive ) male age 18 60 inclusive Previously concurrently diagnose secondary hypogonadism characterize least 2 consecutive morning testosterone assessment &lt; 300ng/dL , one must confirm Baseline . LH &lt; 9.4 mIU/mL ( Visit 1 ) Sperm concentration ≥ 15 million per milliliter ( assessed V2 Baseline ) . V2 Baseline measurement must least 48 hour apart . Ability complete study compliance protocol Ability understand provide write informed consent Agreement provide total least 4 semen sample sponsorapproved clinic 4 separate occasion . Any prior use testosterone treatment ( injectable , pelleted , transdermal sublingual ) within last 6 month Use spironolactone , cimetidine , Clomid , 5αreductase inhibitor , hCG , androgen , estrogen , anabolic steroid , DHEA , herbal hormone product study Use Clomid past year Any clinically significant laboratory abnormality prior write sponsor approval . If sponsor approves subject enrollment , consider protocol deviation . Uncontrolled hypertension diabetes mellitus base Investigator 's assessment baseline . Subjects treat Type II diabetes allow study , consider clinically stable investigator . Newly diagnose diabetic need treat least 48 hour enrol study . A hematocrit &gt; 54 Use investigational drug product , participation drug medical device research study within 30 day prior receive study medication . Known hypersensitivity Clomid Symptomatic cataract ( nuclear sclerosis cataract cortical cataract grade &gt; 2 base 04 scale evidence posterior subcapsular cataract ) Abnormal fundoscopy exam central retinal vein occlusion Any condition opinion investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part study Have receive diagnosis irreversible infertility compromise fertility ( cryptorchism , Kallman Syndrome , primary hypogonadism , vasectomy , tumor pituitary ) , history evaluation treatment low fertility Current history breast cancer Current history prostate cancer suspicion prostate disease unless rule prostate biopsy , PSA &gt; 3.6 Presence history know hyperprolactinemia without tumor ( prolactin &gt; 20 ng/mL ) . Chronic use medication glucocorticoid ( chronic use inhale topical glucocorticoid acceptable ) History drug abuse chronic narcotic use include methadone A recent history alcoholism illegal substance steroid abuse ( &lt; 2 year ) presence moderate alcohol use ( &gt; 21 drink per week ) Subjects known history HIV and/or Hepatitis C Subjects end stage renal disease History liver disease ( include malignancy ) confirm AST ALT &gt; 3 time upper limit normal History clinically relevant myocardial infarction ( within previous year ) , unstable angina , symptomatic heart failure , ventricular dysrhythmia know history QTc interval prolongation History clinically relevant cerebrovascular disease History venous thromboembolic disease ( e.g . deep vein thrombosis pulmonary embolism ) History erythrocytosis polycythemia Subjects unable provide semen sample sponsorapproved clinic Enrollment previous Androxal study Subjects Type I Diabetes</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Low Testosterone</keyword>
</DOC>